ATHANA alliance for antifungal therapy approaches – First strategy workshop
The RUBIN alliance “ATHANA” (antifungal therapy approaches with nanoparticle-based targeting of drugs) met for their first strategy workshop one year after the project kicked off in summer last year.
The meeting was held at the Leibniz Institute for Natural Product Research and Infection Biology (Leibniz-HKI) together with Project Management Jülich (PtJ) represented by Mandy Görgen and Dr. Danny Vogel. The alliance members presented the status-quo of their research and discussed further steps within the project.
Dr. Knut Rennert (CEO and Co-founder Dynamic42) said:
It is particularly encouraging that the milestones were achieved within the agreed time frame and that a lively exchange between the ATHANA partners has been established and expanded over the past year.
As to further enhance transparency and communication around the projects, a redesign of the ATHANA homepage was released.
We thank all ATHANA partners, SmartDyeLivery, Dyomics, BioControl Jena GmbH, Jena Bioscience GmbH, Universitätsklinikum Jena, HAPILA GmbH for a year of great collaboration and the Thüringer ClusterManagement, represented by Dr. Britta Wlotzka, for support of the project.
You can learn more about ATHANA here.
About SmartDyeLivery
SmartDyeLivery from Jena is developing universal platform technology based on functionalised nanoparticles with which medicine or other cargo can be transported specifically to the desired organ. The aim is to provide new therapeutic options for diseases that were previously untreatable or difficult to treat. The innovative, patent-protected technology can also be used for diagnostic or theranostic applications. For more information, please visit www.smartdyelivery.de
About Jena Bioscience (JBS)
JBS has long-standing expertise in the production, preservation and labelling of nucleotides/nucleosides. The company also specialises in the modification of biomolecules with the help of linker systems and coupling methods. For more information, please visit www.jenabioscience.com
About BioControl Jena GmbH (BCJ)
BioControl Jena is a service provider for the analysis and optimisation of biodata and processes, bioinformatics and systems biology, statistics (including consulting), result visualisation and model development in various areas of life sciences. For more information, visit www.biocontrol-jena.com
About Dynamic42 GmbH
D42 was founded in 2018 as a spin-off of the Jena University Hospital. The start-up develops and sells human microphysiological systems (organ-on-chip technology) that enable toxicity screenings and ADMET studies.
About Hapila GmbH
Hapila GmbH, based in Gera, Germany, has extensive expertise in the field of organic synthesis of active ingredients across all stages of development up to clinical trial samples and market products. Hapila has long been familiar with regulatory issues in drug development, GMP manufacturing (quality) and stability testing. For more information, please visit www.hapila.de
About Dyomics GmbH
Dyomics GmbH has many years of experience and extensive expertise in the field of diagnostic fluorescent dyes, which can also be used for selective targeting. For more than 20 years, a proprietary product portfolio has been offered worldwide for a wide range of applications in the life sciences. For more information, please visit www.dyomics.com
About Leibniz-HKI
As an academic institution, Leibniz-HKI has, for many years, been an international leader in research on the infection biology of human-pathogenic fungi and the identification of new anti-infective agents. The Leibniz-HKI is experienced in the development of medicines up to clinical trials and has a library of its own active substances. For more information, please visit www.leibniz-hki.de
About Jena University Hospital (UKJ)
Jena University Hospital (UKJ) is the only university medical centre in Thuringia and the largest employer in the region with almost 7,000 employees. The medical faculty educates 2,700 medical, dental and master’s students. Scientists from over 50 nations do research here. The focus is on sepsis and infection research, ageing and ageing-associated diseases as well as medical optics and photonics. More than 300,000 inpatients and outpatients are treated in the UKJ’s clinics and polyclinics every year. For more information, please visit www.uniklinikum-jena.de
Read more News:
Amélie Marie Paillereau joins Dynamic42 as Master Student funded by the Thuringia and European Social Fund Plus
We are excited to welcome Amélie Marie Paillereau to the Dynamic42 science team. Amélie started in April with us for a 12-month-long Master thesis, focusing on perfused breast and pancreatic cancer-on-chip models to study the impact of the tumor microenvironment on immune cell invasion.
Joanna Nowacka joins Dynamic42 as Lead for Stem Cell Model Development
We are delighted to announce that Joanna Nowacka has joined Dynamic42 as Lead for Stem Cell Model Development.
Cancer, rheumatism, asthma: organ-on-chip models highly relevant for preclinical testing of therapeutic antibodies
Improving people’s lives with innovative technologies. This was the goal that Jena-based Dynamic42 had in mind 18 months ago when they launched a project – funded as part of the Sanofi iDEA-iTECH Award Program.